Editors: Gene D. Morse, Sarah Nanzigu

Series Title: Frontiers in HIV Research

Advances in HIV Treatment: HIV Enzyme Inhibitors and Antiretroviral Therapy

Volume 1

eBook: US $39 Special Offer (PDF + Printed Copy): US $106
Printed Copy: US $87
Library License: US $156
ISSN: 2405-9862 (Print)
ISSN: 2405-9889 (Online)
ISBN: 978-1-68108-057-4 (Print)
ISBN: 978-1-68108-056-7 (Online)
Year of Publication: 2015
DOI: 10.2174/97816810805671150101


Advances in HIV Treatment: HIV Enzyme Inhibitors and Antiretroviral Therapy presents comprehensive and updated information on drug therapies used to treat and manage HIV infection in human patients. The volume is organized in to chapters detailing respective classes of HIV Drugs including HIV entry inhibitors, reverse transcriptase inhibitors (RTIs), integrase strand inhibitors (INSTIs), and protease inhibitors (PIs). Each chapter compiles background information, pharmacology and clinical aspects such as side effects on the specific classes of drugs represented. Available data for ongoing research for new targets, including vaccines is also presented. Readers will also find a useful introduction to HIV virology and pathogenesis as well as a comparison of the availability and activity of these agents in different populations, opening a discussion on the influence of genetics and resources in curbing the HIV epidemic. Advances in HIV Treatment: HIV Enzyme Inhibitors and Antiretroviral Therapy is, therefore, a holistic resource for researchers, healthcare professionals and clinicians interested in understanding antiretroviral drugs and the management of HIV infection/AIDS. The volume is also of interest to undergraduate and graduate students undertaking specialized courses in pharmacology and HIV/AIDS management.


This book focuses on updates in HIV Treatments, an area with a very high turnover of information. Although there aren’t as many new findings related to the human immunodeficiency virus itself, the number of new drugs and targets has grown tremendously since the onset of the epidemic. Treatment guidelines are revised much more often than those of other diseases in order to capture new therapies, changes in regimens, including their indications.

Since the onset of HIV epidemic, more than 30 antiretroviral agents have been approved for use in persons infected with the virus, and those at high risk. Although these drugs are grouped in less than 6 classes, each of them possesses some unique characteristics. These unique attributes can influence vital areas including response to treatment and toxicity profiles. This book is intended to provide compiled and updated information on each of the available and upcoming antiretroviral agents, to assist persons involved in HIV clinical care and research.

The authors have been selected based on their expertise in HIV/AIDS, and we greatly appreciate your valued input into this work. We trust that our esteemed readers will find this information to be of great value.

Gene D. Morse
New York State Center of Excellence in Bioinformatics and Life Sciences
University at Buffalo (UB),
Buffalo, Newyork
Sarah Nanzigu
Department of Pharmacology and Therapeutics
Makerere University College of Health Science


.Emerging Approaches to Tackle Neglected Diseases: From Molecule to End Product.
.COVID 19 – Monitoring with IoT Devices.
.Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents.
.Recent Trends and The Future of Antimicrobial Agents - Part 2.